AJG: 新末端回肠的术后内镜复发是克罗恩病的长期预后预测因素

2020-07-03 MedSci原创 MedSci原创

克罗恩病患者术后第一年内进行早期回肠结肠镜检查是评估回肠结肠切除术克罗恩病(CD)复发率的金标准。本项研究的目的是评估术后早期结肠镜检查中吻合口和回肠病变的存在与严重程度与疾病长期预后之间的关系。

背景及目的:

克罗恩病患者术后第一年内进行早期回肠结肠镜检查是评估回肠结肠切除术克罗恩病(CD)复发率的金标准。本项研究的目的是评估术后早期结肠镜检查中吻合口和回肠病变的存在与严重程度与疾病长期预后之间的关系。

 

方法:

本项研究是一项前瞻性多中心研究,纳入了包括接受回肠或回结肠CD手术的患者,所有患者术后6个月进行结肠镜检查。研究人员分别建立了描述吻合和回肠病变的内窥镜评分。临床复发是由CD相关症状定义的,并通过影像学,内窥镜检查或治疗强化证实。

 

结果:

在225名患者中,有193名接受了长期随访(中位随访时间:3.82年)。中位无复发生存期为47.6个月。与无回肠病变的患者(I(0))相比,术后早期内镜下有回肠病变的患者无论其严重程度为(I(1)或I(2,3,4)),其临床无复发生存期均明显缩短( I(0)vs I(2,3,4):P = 0.0003; I(0)vs I(1):P = 0.0008和I(1)vs I(2,3,4):P = 0.43) 。仅具有回肠病变的患者(A(0)I(1,2,3,4))的临床长期结局要比仅具有回肠病变的患者(A(1,2,3)I(0))(P = 0.009)要好。

 

讨论:

本项研究证实对克罗恩病术后患者分别描述吻合口和回肠病变的评分可能更适合定义术后内镜复发。治疗具有回肠病变的患者(包括轻度回肠病变(I(1)))以改善长期预后。

原始出处:

Hammoudi, Nassim. Et al. Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. The American Journal of Gastroenterology. 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2021-01-30 minzju5052
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-08 148130fbm86(暂无昵称)

    腻害腻害

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-05 Tamikia
  7. [GetPortalCommentsPageByObjectIdResponse(id=2057312, encodeId=302e205e312dd, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sat Jan 30 02:15:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645631, encodeId=0340164563124, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Sun May 23 05:15:51 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801691, encodeId=b4a080169125, content=腻害腻害, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b425266515, createdName=148130fbm86(暂无昵称), createdTime=Wed Jul 08 06:33:49 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262191, encodeId=371c126219155, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264335, encodeId=687e126433582, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511365, encodeId=506e1511365e3, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Sun Jul 05 00:15:51 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801051, encodeId=b0dd8010511d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=becf1738887, createdName=芬太尼注射液, createdTime=Fri Jul 03 10:42:52 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-03 芬太尼注射液

    学习了。

    0

相关资讯

Gastroenterology:Upadacitinib治疗中重度克罗恩病II期临床获得成功

Upadacitinib治疗可提高克中重度克罗恩病患者内镜缓解率

JCC: CT和MR在诊断回肠型克罗恩病患者中的作用

本项研究是确定在具有正常回肠镜的克罗恩病患者中,在计算机断层扫描或磁共振肠造影在判断回肠炎症的重要性。

Lancet Gastroen Hepatol:Ozanimod用于中重度克罗恩病的治疗

Ozanimod治疗可改善中重度克罗恩病患者内窥镜检查、组织学和临床反应

Lancet Gastroen Hepatol:腹腔镜回肠切除术 vs英夫利昔单抗治疗回肠炎型克罗恩病

研究支持采用腹腔镜回肠切除术作为克罗恩病的治疗选择,特别是针对局限性(受累节段≤40 cm)和以炎性末端回肠炎为主,常规治疗不成功的患者

IBD:细菌组成和功能可预测小儿克罗恩病的单一肠内营养治疗后持续缓解情况

肠道微生物组通过影响单一肠内营养(EEN)的疗效而广泛参与小儿克罗恩病(CD)患者的缓解情况。

IBD:克罗恩病回肠切除吻合术后的吻合口溃疡很常见并且可以预测复发

回肠切除吻合术后克罗恩病的复发很常见。吻合口溃疡是否代表疾病复发并应纳入评分系统尚有争议。这项研究的目的是确定吻合口溃疡对先前进行回盲切除吻合的患者克罗恩病复发的影响。